Biased Agonism in Drug Discovery: Clinical Promise and Pitfalls

The discovery of biased agonism as a pharmacological technique that enables specific receptor pathway activation through ligands transformed receptor pharmacology. The analysis evaluates the fundamental mechanisms and medical implications alongside the development hurdles for biased agonist drug discovery. The research analyzed PubMed alongside Scopus and Web of Science databases for articles between 2000 and 2024 under keywords that included "biased agonism" "GPCR signalling" and "functional selectivity." The review included articles about biased agonist mechanistic aspects together with clinical applications and regulatory frameworks. The study demonstrates how biased agonism enables therapeutic benefits through reduced unwanted effects specifically within opioid and adrenergic signalling pathways. Clinical studies of oliceridine and carvedilol demonstrate proof-of-concept yet their transition from laboratory research to clinical applications faces ongoing challenges. The context-dependent nature of receptor signalling together with methodological inconsistencies prevents accurate translation. Our analysis reveals the main challenges of assay inconsistency together with regulatory ambiguity and the reduction of complex signalling to simple dichotomies. New technologies which include cryo-EM organoids and AI-driven ligand screening systems provide predictive frameworks to scientific research. The practice of precision pharmacotherapy shows great potential through biased agonism. Biased agonism requires collaboration between different fields together with improved biomarkers and revised regulatory standards to achieve full therapeutic benefits.